BIIB Stock Price Today (July 2026) — Biogen Inc. Analysis & Key Metrics 2026-07-17
Biogen Inc. (BIIB) is trading at $205.99, down 1.40% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $220.28 (6.9% upside).
- Volatility remains elevated (48.54% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (1.90% YoY) alongside significant competitive pressures.
BIIB Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Biogen Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $34.18B
P/E Ratio
Forward P/E: 12.65
Revenue Growth
Year over Year
Analyst Target
+6.9% upside potential
Key Investor Questions About BIIB
What investors need to know before buying
Based on current market data, BIIB presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 51.84)
- Fundamentals say: Caution warranted (high leverage concerns)
BIIB's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BIIB investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $6.56B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BIIB stock traded between $121.05 and $219.72—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 48.54% annualized volatility and β=0.54, the stock exhibits low sensitivity to market moves—making BIIB suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Slate Medicines Appoints Mark W. Hahn to Board of Directors
By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...
IBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today’s Market
FEATURE The and the tech-heavy were up Tuesday, led by the resurgent artificial-intelligence trade, as investors responded to cooler-than-expected U.S. inflation data for June, a slew of bank earnings reports, and a profit warning from IBM.
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update dur
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study
Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem
The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.
Frequently Asked Questions
Common investor questions about Biogen Inc.
Biogen Inc. (BIIB) is currently trading at $205.99. The RSI (14-day) is at 51.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $220.28 implies 6.9% upside from current levels. Volatility is high at 48.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Biogen Inc. (BIIB): The trailing P/E ratio is 22.17, which is in line with broader market averages. The forward P/E is 12.65, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 4.55, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.63. Price-to-Sales is 3.06. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 31 analysts covering BIIB, the consensus price target is $220.28. This represents a 6.9% upside from the current price of $205.99. The range spans from a low target of $150.00 to a high target of $300.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Biogen Inc. (BIIB) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Biogen Inc. (BIIB) investors include: 1. High volatility (48.5% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Biogen Inc.'s (BIIB) current debt and financial health profile: Total debt stands at $6.56B. The debt-to-equity ratio is 35.18, which is moderate and generally manageable for most companies. The current ratio is 3.06, indicating strong short-term liquidity. The quick ratio is 2.02. The company holds $4.28B in cash and equivalents. Free cash flow is positive at $1.93B, providing a cushion for debt servicing and shareholder returns.